Friedreich’s ataxia (FA) is a rare, autosomal recessive neurodegenerative disease whose natural history and clinical characterization have made significant progress in recent decades. Nevertheless, there is still a lack of sensitive, objective biomarkers that both reliably reflect disease progression and are practicable for clinical studies. The TRACK-FA study, the largest multicenter, multimodal neuroimaging study in FA to date, is now making a decisive contribution. It shows that structural and functional imaging markers not only detect disease-relevant changes, but also correlate with clinical scales. This opens up new avenues for more precise diagnostics, the development of therapies and the shortening of study durations.
Autoren
- Tanja Schliebe
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Wound Care
Chronically infected wound on the lower leg – a case report
- From symptom to diagnosis
Dyspnea – thoracic lymphoma
- Hemophilia A and B
Personalized approach and innovative treatment options
- Diagnosis and treatment of neurological and psychiatric illnesses
Precision Neurology
- Type 2 diabetes
Pharmacotherapy can lead to remission
- Case Report
Mycosis fungoides in an 11-year-old child
- EHA 2025
Progress in multiple myeloma
- Interstitial lung diseases